Workflow
石四药集团午后跌超5% 上半年纯利同比下降58.7% 中期息减至5港仙

Core Viewpoint - The company reported a significant decline in both sales revenue and profit for the first half of 2025, indicating potential challenges in its business operations and market conditions [1] Financial Performance - Sales revenue for the first half of 2025 was approximately 2.147 billion HKD, a year-on-year decrease of about 35.7% [1] - Profit attributable to equity holders was approximately 283.5 million HKD, down 58.7% year-on-year [1] - Earnings per share were 0.0962 HKD, with an interim dividend of 0.05 HKD compared to 0.08 HKD in the same period last year [1] Business Segments - The infusion business experienced a significant decline, with sales volume of approximately 715 million bottles (bags), a year-on-year decrease of 37%, and sales revenue of 1.199 billion HKD, down 45% [1] - In the water injection segment, ampoule water injection sales volume was 17.818 million units, a year-on-year increase of 7%, but sales revenue fell to 157 million HKD, a decrease of 57% [1] - The oral formulation segment saw a sales revenue of 296 million HKD, reflecting a year-on-year growth of 16% [1] - The active pharmaceutical ingredients segment reported sales revenue of 361 million HKD, down 9.6% year-on-year [1]